相关实验视频
Updated: Jul 10, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
乌帕达西丁:作用机制,临床和翻译科学
Mohamed-Eslam F Mohamed1, Sumit Bhatnagar1, Julie M Parmentier2
1Clinical Pharmacology, AbbVie, North Chicago, Illinois, USA.
Clinical and translational science
|November 20, 2023
概括
乌帕达西提尼布是一种选择性简氏激酶 (JAK) 抑制剂,通过阻断关键细胞因子信号通路,有效治疗慢性炎症疾病. 临床试验证实了其在多种自身免疫性疾病中的有效性和良好的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 乌帕达西尼布是一种被批准用于治疗慢性炎症疾病的选择性简氏激酶 (JAK) 抑制剂.
- 它针对关键的细胞因子信号传递途径,涉及免疫介导的炎症性疾病.
研究的目的:
- 为了审查upadacitinib的作用机制.
- 描述JAK-STAT通路在炎症性疾病中的作用.
- 提供对支持上达西提尼布开发和剂量的临床试验的概述.
主要方法:
- 对乌帕达西提尼布的药理动力学,药理动力学,疗效和安全性的审查.
- 对各种炎症状况的临床试验数据的分析.
- 检查JAK-STAT途径在疾病发病过程中的作用.
主要成果:
- 在类风湿性关节炎,牛皮性关节炎,化性脊髓炎等方面,乌帕达西提尼比安慰剂或活性比较剂更有效.
- 与其他JAK异型相比,该药物优先抑制JAK1.
- 临床试验在批准的适用症候群中确定了对upadacitinib的有利益处风险概况.
结论:
- 乌帕达西尼布是多种慢性炎症疾病的有效治疗方法.
- 它的选择性JAK抑制为管理免疫介导疾病提供了有针对性的方法.
- 临床证据支持upadacitinib在治疗诸如类风湿性关节炎和炎症性肠病等疾病中的作用.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Activation of Integrins
3.5K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176

